Literature DB >> 10801025

Resection or transplantation for hepatocellular carcinoma in cirrhotic patients: outcomes based on indicated treatment strategy.

J Figueras1, E Jaurrieta, C Valls, E Ramos, T Serrano, A Rafecas, J Fabregat, J Torras.   

Abstract

BACKGROUND: Surgical resection has been the treatment of choice for hepatocellular carcinoma (HCC), but the resection rate remains low in cirrhotic patients and recurrence is common. Unfavorable results compared with benign disease and the shortage of organ donors have led to a restricted indication for orthotopic liver transplantation (OLT) for HCC. STUDY
DESIGN: The aim of this study was to analyze the results of our surgical approach to HCC in patients with cirrhosis. The first treatment strategy indicated in these patients was OLT. From January 1990 to May 1999, 85 patients underwent OLT and the remaining 35 had surgical resection.
RESULTS: One-, 3-, and 5-year survival rates were 84%, 74%, and 60% versus 83%, 57%, and 51%, respectively, in the OLT and resection groups (p = 0.34). Hepatic tumor recurrence was much less frequent in the OLT group than in the resection group. The 1-, 3-, and 5-year disease-free survival rates were 83%, 72%, and 60% versus 70%, 44%, and 31%, respectively (p = 0.027). In the multivariate Cox regression analysis, macroscopic vascular invasion was the only factor independently associated with death or recurrence after OLT (p = 0.006). After partial liver resection, the tumors significantly associated with mortality and recurrence in the multivariate analysis were solitary or multiple tumors greater than 2cm with microscopic vascular invasion (pathologic pT3) (p = 0.01).
CONCLUSIONS: Our results confirm that in cirrhotic patients, OLT may provide better outcomes than liver resection in carefully selected HCC and that longterm survival is similar to the results of OLT in cirrhotic patients without tumors.

Entities:  

Mesh:

Year:  2000        PMID: 10801025     DOI: 10.1016/s1072-7515(00)00251-9

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  51 in total

1.  Growth rate of primary single hepatocellular carcinoma: determining optimal screening interval with contrast enhanced computed tomography.

Authors:  Kazunori Kubota; Hiroyasu Ina; Yoichi Okada; Tetsuya Irie
Journal:  Dig Dis Sci       Date:  2003-03       Impact factor: 3.199

Review 2.  Optimizing hepatectomy for hepatocellular carcinoma in Asia-patient selection and special considerations.

Authors:  Clarence Nicholas Kotewall; Tan To Cheung
Journal:  Transl Gastroenterol Hepatol       Date:  2018-10-08

3.  Liver transplantation, liver resection, and transarterial chemoembolization for hepatocellular carcinoma in cirrhosis: which is the best oncological approach?

Authors:  Georgios C Sotiropoulos; Nina Drühe; George Sgourakis; Ernesto P Molmenti; Susanne Beckebaum; Hideo A Baba; Gerald Antoch; Philip Hilgard; Arnold Radtke; Fuat H Saner; Silvio Nadalin; Andreas Paul; Massimo Malagó; Christoph E Broelsch; Hauke Lang
Journal:  Dig Dis Sci       Date:  2008-12-05       Impact factor: 3.199

4.  Orthotopic liver transplantation as a rescue operation for recurrent hepatocellular carcinoma after partial hepatectomy.

Authors:  Zhuo Shao; Rocio Lopez; Bo Shen; Guang-Shun Yang
Journal:  World J Gastroenterol       Date:  2008-07-21       Impact factor: 5.742

Review 5.  Treatment outcomes of transcatheter arterial chemoembolization combined with local ablative therapy versus monotherapy in hepatocellular carcinoma: a meta-analysis.

Authors:  Lili Gu; Huiling Liu; Linlin Fan; Yuanjun Lv; Zhuang Cui; Yan Luo; Yuanyuan Liu; Guang Li; Changping Li; Jun Ma
Journal:  J Cancer Res Clin Oncol       Date:  2014-02       Impact factor: 4.553

6.  Percutaneous ethanol injection, radiofrequency and their combination in treatment of hepatocellular carcinoma.

Authors:  Bao-Ming Luo; Yan-Ling Wen; Hai-Yun Yang; Hui Zhi; Xiao-Yun Xiao; Bing Ou; Jing-Sheng Pan; Jian-Hong Ma
Journal:  World J Gastroenterol       Date:  2005-10-28       Impact factor: 5.742

7.  Primary surgical resection versus liver transplantation for transplant-eligible hepatocellular carcinoma patients.

Authors:  Robert J Wong; James Wantuck; Antonia Valenzuela; Aijaz Ahmed; Clark Bonham; Amy Gallo; Marc L Melcher; Glen Lutchman; Waldo Concepcion; Carlos Esquivel; Gabriel Garcia; Tami Daugherty; Mindie H Nguyen
Journal:  Dig Dis Sci       Date:  2013-11-27       Impact factor: 3.199

Review 8.  Irreversible electroporation of hepatic malignancy.

Authors:  Govindarajan Narayanan; Tatiana Froud; Rekhaben Suthar; Katuska Barbery
Journal:  Semin Intervent Radiol       Date:  2013-03       Impact factor: 1.513

9.  MR characterisation of dysplastic nodules and hepatocarcinoma in the cirrhotic liver with hepatospecific superparamagnetic contrast agents: pathological correlation in explanted livers.

Authors:  L Macarini; P Milillo; A Cascavilla; G Scalzo; L Stoppino; R Vinci; G Moretti; G Ettorre
Journal:  Radiol Med       Date:  2009-11-09       Impact factor: 3.469

10.  Good longterm survival after primary living donor liver transplantation for solitary hepatocellular carcinomas up to 8 cm in diameter.

Authors:  Wing Chiu Dai; See Ching Chan; Kenneth S H Chok; Tan To Cheung; William W Sharr; Albert C Y Chan; Simon H Y Tsang; James Y Y Fung; Ronnie T P Poon; Sheung Tat Fan; Chung Mau Lo
Journal:  HPB (Oxford)       Date:  2014-01-28       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.